About us

Our name, Enara Bio®, is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in discovering and validating Dark Antigens®, a rich source of novel cancer targets derived from areas of the genome previously considered to be ‘dark’ or non-coding. Through our proprietary EnTiCE® platform, we are developing first-in-class bispecific T-cell engagers against novel targets to improve treatment outcomes for broad populations of cancer patients.

Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer
Stacey Davis
Chief Business Officer and Chief Financial Officer

Board of Directors

Scientific Advisors & Founders

Investors

Rana Al-Hallaq

Director

Rana Al-Hallaq, PhD is Partner and Head of Operations at Pfizer Ventures and Vice President, Worldwide Business Development. Rana is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She is also responsible for managing investments in the Dementia Discovery Funds, the Health Enterprise Partners Fund, and the Wellington Venture Investments Fund. Rana serves as Vice Chair on the New York BIO Board of Directors.

Prior to her current role, Rana was a Transactions specialist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. Rana joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies. Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas. She began her training as a research fellow at the National Institutes of Health.

Rana graduated Summa Cum Laude and Phi Beta Kappa with a BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.